- Home
- PRLD vs AIRG Comparison
PRLD vs AIRG Comparison
Compare PRLD & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- AIRG
- Stock Information
- Founded
- PRLD 2016
- AIRG 1995
- Country
- PRLD United States
- AIRG United States
- Employees
- PRLD N/A
- AIRG N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- AIRG Radio And Television Broadcasting And Communications Equipment
- Sector
- PRLD Health Care
- AIRG Technology
- Exchange
- PRLD Nasdaq
- AIRG Nasdaq
- Market Cap
- PRLD 44.0M
- AIRG 48.9M
- IPO Year
- PRLD 2020
- AIRG 2016
- Fundamental
- Price
- PRLD $1.03
- AIRG $4.34
- Analyst Decision
- PRLD Strong Buy
- AIRG Strong Buy
- Analyst Count
- PRLD 3
- AIRG 3
- Target Price
- PRLD $4.00
- AIRG $8.50
- AVG Volume (30 Days)
- PRLD 231.3K
- AIRG 29.5K
- Earning Date
- PRLD 11-05-2025
- AIRG 11-11-2025
- Dividend Yield
- PRLD N/A
- AIRG N/A
- EPS Growth
- PRLD N/A
- AIRG N/A
- EPS
- PRLD N/A
- AIRG N/A
- Revenue
- PRLD $7,000,000.00
- AIRG $56,820,000.00
- Revenue This Year
- PRLD N/A
- AIRG N/A
- Revenue Next Year
- PRLD N/A
- AIRG $21.58
- P/E Ratio
- PRLD N/A
- AIRG N/A
- Revenue Growth
- PRLD N/A
- AIRG 6.84
- 52 Week Low
- PRLD $0.61
- AIRG $3.17
- 52 Week High
- PRLD $2.72
- AIRG $10.34
- Technical
- Relative Strength Index (RSI)
- PRLD 45.61
- AIRG 50.42
- Support Level
- PRLD $1.03
- AIRG $4.03
- Resistance Level
- PRLD $1.26
- AIRG $4.39
- Average True Range (ATR)
- PRLD 0.11
- AIRG 0.19
- MACD
- PRLD -0.03
- AIRG 0.02
- Stochastic Oscillator
- PRLD 10.34
- AIRG 61.72
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.